尼洛替尼治疗伊马替尼耐药或不耐受慢性髓系白血病患者的临床研究

本研究目的旨在评价尼洛替尼治疗伊马替尼耐药或不耐受的慢性髓系白血病（CML）患者的疗效及安全性。23例伊马替尼耐药或不耐受的CML患者纳入本研究。患者每日口服尼洛替尼600-800 mg,对他们的疗效、总体生存和耐受情况进行评估。结果表明,23例接受尼洛替尼治疗的患者中,全部获得完全血液学缓解（CHR）,19例（82.6%）获得完全细胞遗传学缓解（CCyR）,13例（56.5%）获得完全分子学缓解（CMR）,中位尼洛替尼治疗时间13.5（1-44）个月,中位随访时间40（12-102）个月。尼洛替尼治疗后的不良反应大半为轻微的,而且可以逆转。结论：尼洛替尼治疗伊马替尼耐药的CML患者疗效佳,患者耐受性好。

Nilotinib Treatment for Patients with Imatinib-Resistant or Intolerant Chronic Myeloid Leukemia

This study was purposed to evaluate the efficacy and safety of nilotinib for treating patients with imatinibresistant or intolerant chronic myeloid leukemia（ CML）.A total of 23 patients with imatinib-resistant or intolerant CML were enrolled in this study.These patients received nilotinib orally 600- 800 mg every daytheir curative efficacytolerance and overal survival were evaluated.The results showed that all the patients treated with nilotinib obtained complete hematologic remission（ CHR）,out of them 82.6% patients achieved complete cytogenetic remission（ CCyR）and 56.5% patients achieved complete molecular remission（ CMR）,their adverse events mostly were mild to moderategenerally were transient and easily curedthe median treatment time with nilotinib was 13.5（ 1- 44 ）monthsand the median follow-up time was 40（ 12- 102 ）months.It is concluded that nilotinib has been confirmed to be effective for patients with imatinib-resistant or intolerant CMLand may be selected as a second generation of tyrosine kinase inhibitor（TKI）.